ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- Resource Type
- Journal
- Source
ANNALS OF ONCOLOGY ; DEC 2020, 31 12, p1606-p1622, 17p.- Subject
- Language
- English
- ISSN
- 15698041